Strive Lists New Preferred Stock With 15% Dividend on Nasdaq
Strive's SATS preferred stock, paying a 15% daily dividend, started trading on Nasdaq after an upsized IPO of 7 million shares at $90 each.
CoreWeave's stock has fallen by more than half since the Nasdaq 100 inclusion, as insiders unloaded $740m in shares.
Mike Intrator, the chief executive of CoreWeave, offloaded around $85m of shares in the indebted artificial intelligence firm from 15 to 30 September.
Those shares have since shed over a quarter of their value.
The company is seeing widespread insider selling, with its stock having dropped $18bn in market capitalisation and over 46% in price since it entered the Nasdaq 100 index.
This week, McBee informed the Financial Times that CoreWeave plans to take on additional debt.
The CEO has been offloading a consistent weekly block of roughly 307,700 shares, yet the proceeds have been shrinking in line with the falling stock price.
Taken together, CoreWeave's officers and directors have offloaded roughly $740m of stock since the company entered the usually prestigious Nasdaq 100 index on 22 June.
The stock opened that day at close to $119 but started trading today below $62. The company's lenders are pricing in distress.
The firm's borrowing cost on bonds maturing in 2031 climbed above 16%, approaching credit card rates.
Credit default swaps on CoreWeave indicated a roughly 63% probability of default within five years.
As of the end of June, the company had around $52bn in total debt and lease liabilities.
Share to
Disclaimer: this article comes from third-party media and is provided for reference only. It does not constitute investment advice. Crypto and other financial products carry significant price volatility risk, so please make your own decisions carefully.
Strive's SATS preferred stock, paying a 15% daily dividend, started trading on Nasdaq after an upsized IPO of 7 million shares at $90 each.
STRC has traded under $100 since May despite Strategy's buybacks, and MSCI's delisting decision added further pressure.
Gemini shares hit a record-low $3.215 close, about 89% below the $28 IPO price; H1 2026 revenue rose and the loss narrowed.
A healthcare technology company is shifting most AI workloads to open-weight and small models, achieving major cost savings while maintaining performance.